Smith & Nephew PLC (SNN) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Smith & Nephew PLC (SNN)

30.90

-0.42 (1.34%)

as of Jun 10, 2026, 8:00:00 pm Market Open.

33 watching

Investor Insights

Jun 10, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Smith & Nephew PLC (SNN-N) has increasingly garnered positive reviews, particularly due to successful management changes over the past four years that have led to improved revenue, profitability, and brand recognition. Analysts highlight the company's strong position in the orthopedic market, offering joint repairs and dressings, and note that it's currently trading at approximately half the price of its chief competitor, Stryker. Many experts see a bright future for the stock, citing expected margin improvements and industry growth. As a UK company, it appears to be undervalued compared to similar firms, yet the recent changes in management and investments in R&D suggest potential for significant operational and stock price upside. There's a consensus among analysts that Smith & Nephew represents a compelling investment opportunity at present.

Consensus

Buy

Valuation

Undervalued

Similar

SYK

TOP PICK

Knee replacements. Nicely situated within this industry. Aging population will create a demand.

TOP PICK

Has the least invasive of all the hip and knee replacements out there. Leaders in wound care management for burn and fire victims. A third business is endoscopy components. People have been putting off getting their hips repaired, but eventually they have to step up to the plate. Recovery time is faster. Stock trading at 9-10 times earnings. They came out with blow out margins but some analysts think this is a one-time thing.

PAST TOP PICK

(Top Pick Jan 30, 2009, Up 28%) Hip and Knees. Has just started to wake up. Trading at 9 or 10 times earnings. Cheap in it’s sector.

TOP PICK

Manufactures artificial hips and knees as well as bandages for fire victims and endoscopic devices. Revenues have been sluggish. Release their quarterly figures and revenues were flat but profits grew. People are delaying hips/knee surgeries but that is building a potential for down the road. Buy on weakness.

TOP PICK

Manufactures replacement knees and joints as well as a technology “Mood Management”. Has been vastly oversold and this is a good entry point.

TOP PICK

Hip, knee replacements and endoscopic equipment and wound care management. Equipment is less invasive than its peers. Trading at 10X earnings but growing at 15% to 20% so the PEG ratio is in his favour. People are holding back on getting hips replaced but at some point in time they will have to. 2.3% dividend.

TOP PICK

(London exchange.) Artificial hips and knees. Business will slow down because people will put off having it done but at some point it is going to have to be done. Very strong free cash flow. Also in wound care management which has been very strong.

TOP PICK

They have hip replacement – least invasive so outselling competitors; advanced wound care management using brand new vacuum technology; and endoscopy. Starting to move right now. Held back because most device companies got caught with SCC accusations.

TOP PICK

Manufacture hip and knee replacements. With an aging population and an increasing heavier population, there is more demand for their product.

TOP PICK

Manufacturer of hips and knees, limb care management. Trading at about half the value of its peer group. Demographics are in their favour. Dividend growth rate has been in the 25% range.

TOP PICK

Democratically, the growth in hip and knee replacement is in the 6/13% range per annum. The entire sector has been knocked down in the last year and a half because of FDA problems in price fixing by a lot of that has started to clear away.

BUY

Demographics are all still in favour of the medical device companies. They've all been hit. Demand for hips and knee joints will continue to grow. At a good price now.

TOP PICK

The entire sector has been hit in the last 6 months. Oversold. Dividend.

TOP PICK

A play on the aging of the population.

DON'T BUY

In a great space. Good organic growth opportunities. Was profitable. Concerned with management.

Showing 31 to 45 of 46 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Smith & Nephew PLC (SNN)